Accelerate Diagnostics to Report Preliminary Fourth Quarter and Full Year 2016 Results on February 27th
February 23 2017 - 4:19PM
Accelerate Diagnostics, Inc. today announced it will report
preliminary fourth-quarter and full year 2016 financial results on
Monday, February 27th, 2017.
President and Chief Executive Officer, Lawrence
Mehren, joined by Steve Reichling, Chief Financial Officer, will
host a conference call to review the results at 4:15 p.m. ET.
Fourth quarter and full year audited financial
results will be filed on Form 10-K through the company’s website at
http://ir.axdx.com and through the Securities and Exchange
Commission's (SEC) website at http://www.sec.gov.
The company is completing its financial closing and
auditing procedures for the fiscal year ended December 31, 2016,
and these preliminary results are estimates. Investors are
cautioned not to place undue reliance on preliminary estimates in
the event of material changes.
Conference Call
To participate in the conference call, dial
+1.877.883.0383 and enter the conference ID: 2997883.
International participants may dial
+1.412.902.6506. Please dial in 10-15 minutes prior to the start of
the conference. A replay of the call will be available by telephone
at +1.877.344.7529 (U.S.) or +1.412.317.0088 (international) using
access code 10101155 until March 14, 2017.
About Accelerate Diagnostics,
Inc.
Accelerate Diagnostics, Inc. (“Accelerate
Diagnostics,”) (Nasdaq:AXDX), is an in vitro diagnostics company
dedicated to providing solutions for the global challenge of
antibiotic resistance and hospital acquired infections. The
company's fully automated Accelerate Pheno™ system, and direct from
positive blood culture Accelerate PhenoTest™ BC kit, leverage a
suite of technologies to eliminate the lengthy culture and sample
preparation steps required prior to testing. Using proprietary
molecular identification methods and morphokinetic cellular
analysis (MCA), the solution aims to reduce the time that
clinicians must wait for quantitative antimicrobial susceptibility
results necessary for optimal antibiotic selection, dosing, and
infusion strategy, called minimum inhibitory concentrations, or
MICs.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO”
and “ACCELERATE PHENOTEST” logos and marks are trademarks or
registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its
products or technology, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press
release are forward looking, such as those, among others, about our
projections as to when certain key business milestones may be
achieved, including obtaining marketing authorization by the FDA of
the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for
positive blood cultures, the commercial launch of the Accelerate
Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood
cultures, the potential of our technology, the growth of the
market, our estimates as to the size of our market opportunity and
potential pricing, our competitive position and estimates of time
reduction to results, and our future development plans and growth
strategy. Actual results or developments may differ materially from
those projected or implied in these forward-looking statements.
Information about the risks and uncertainties faced by Accelerate
Diagnostics is contained in the section captioned “Risk Factors” in
the company's most recent Annual Report on Form 10-K, filed with
the Securities and Exchange Commission on March 9, 2016, and in any
other reports that we file with the Securities and Exchange
Commission from time to time. In addition, the company's
forward-looking statements could be affected by general industry
and market conditions. Except as required by federal securities
laws, the company undertakes no obligation to update or revise
these forward-looking statements to reflect new events,
uncertainties or other contingencies.
Investors May Contact:
Laura Pierson, Accelerate Diagnostics, +1 520 365-3100
investors@axdx.com
Reporters May Contact:
Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100
achasteen@axdx.com
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Apr 2023 to Apr 2024